Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells
21 July 2015
Company: ReproCELL,Inc. (Company code:4978) Representative: Chikafumi Yokoyama, PhD Contact: info-us@reprocell.com This is a notice that we will on August 3rd commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the cr...
Announcement of Award for Prototype Development of a Liver Cell Kit
01 July 2015
Announcement: FY 2014-2015 Grant (Additional) for Manufacturing, Commerce, and Service Innovation Has Been Awarded to “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem Cells for Applications i...
Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
30 June 2015
We are pleased to announce that Stemgent Inc. (Cambridge, MA), a REPROCELL Group Company (Yokohama, Japan – JASDAQ: 4978) has launched its new Stemgent StemRNA™-SR Reprogramming Kit, the first commercially available RNA reprogramming kit ap...
REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells
04 June 2015
We are pleased to announce that our company has entered into an exclusive distribution and licensing agreement with Keio University regarding the myocardial cells originating from disease type iPS cells (derived from patients with hypertrop...
Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).
20 April 2015
Sedgefield, UK. April 2015 – Market leading 3D cell culture company Reinnervate Ltd, part of the ReproCELL group, today announced that a rocket carrying its Alvetex® Scaffold technology blasted into Space this week. Alvetex will be used in ...
New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system
05 March 2015
A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells. The cells formed spontaneously active, functional neuronal networks which were not seen in ...
RSC book publication: Human-based systems for translational research
02 February 2015
Biopta's CEO publishes a review of functional human tissue assays in a new book entitled "Human-based systems for translational research", edited by Dr Robert Coleman and published by the Royal Society of Chemistry. The book covers all aspe...
Biopta and Proteon publish new research in Journal of Cardiovascular Pharmacology
13 January 2015
A new paper in the Journal of Cardiovascular Pharmacology describes a potential treatment for atherosclerosis. Proteon Therapeutics, Waltham, MA, has developed a recombinant pancreatic elastase that was tested for its ability to dilate athe...
Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca
08 October 2014
Scientists at AstraZeneca in the UK have compared the activity of a diverse compound set in 2D and 3D cell cultures using Alvetex® Scaffold 384 well plates in an automated Oncology HTS (High Throughput Screening) setting. AstraZeneca report...
REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)
09 September 2014
YOKOHAMA, Japan — REPROCELL (JASDAQ:4978) announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. This acquisition allows the REPROCELL Group to expand the product lineups of its iPS Cell Business and establish technical...